The company line is that there weren't enough sales of the product to support its continued manufacture.
The real truth is that sales of nandrolone skyrocketed after the favorable HIV studies came out. Because Deca is not currently indicated for wasting and that use is considered "off label", and there is a large on going study in AIDS patients using Deca, my guess is that Organon is waiting on the results of the study and if favorable will apply to the FDA for use in wasting, reintroduce the product and jump the price tenfold similar to oxandrolone and anadrol. Imagine one 200 mg 1 ml vial of Deca selling for $200.
Funny how Congress finds time to investigate steroid use in baseball, but they don't give a shit about drug companies using the HIV cash cow to make millions on people suffering from an incurable disease. Furthermore, I don't understand why insurance companies don't demand generic versions of these products to cut costs, instead they just refuse to cover the drug. In the end, the patient gets screwed.
I'm really glad politicians are looking out for the best interests of the people.
W6